A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia

References

• Wuorimaa T, Käyhty H. Current state of pneumococcal vaccines. Scand J Immunol. 2002;56(2):111–11. doi:10.1046/j.1365-3083.2002.01124.x.
   PubMed Web of Science ®Google Scholar
• Maalej SM, Kassis M, Rhimi FM, Damak J, Hammami A. Bacteriology of community acquired meningitis in Sfax, Tunisia (1993-2001). Med Mal Infect. 2006;36(2):105–10. doi:10.1016/j.medmal.2005.10.011.
   PubMed Web of Science ®Google Scholar
• Sfaihi L, Kamoun F, Kamoun T, Aloulou H, Mezghani S, Hammemi A, Hachicha M. Bacterial meningitis in children: epidemiological data and outcome. Tunis Med. 2014;92:141–46.
   PubMedGoogle Scholar
• Haddad-Boubaker S, Lakhal M, Fathallah C, Mhimdi S, Bouafsoun A, Kechrid A, Smaoui H. Epidemiological study of bacterial meningitis in Tunisian children, beyond neonatal age, using molecular methods: 2014-2017. Afr Health Sci. 2020;20(3):1124–32. doi:10.4314/ahs.v20i3.14.
   PubMed Web of Science ®Google Scholar
• Belkhouja K, Ben Romdhane K, Ghariani A, Ben Khelil J, Besbes M, Ghariani A, M’-Hiri E, Slim-Saidi L. Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU. J Infect Chemother. 2012;18(3):324–31. doi:10.1007/s10156-011-0337-8.
   PubMed Web of Science ®Google Scholar
• Thabet F, Tilouche S, Tabarki B, Amri F, Guediche MN, Sfar MT, Harbi A, Yacoub M, Essoussi AS. Pneumococcal meningitis mortality in children. Prognostic factors in a series of 73 cases. Arch Pediatr. 2007;14(4):334–37. doi:10.1016/j.arcped.2006.11.012.
   PubMed Web of Science ®Google Scholar
• Ben Salah A, El Mhamdi S, Ben Fredj M, Ben Meriem C, Bouguila J, Ben Helel K, Sfaihi L, Mustapha R, Sfar M, Soltani M, et al. Hospital costs of invasive pneumococcal disease in children under 15 years of age in Tunisia. Emhj. 2019;25(12):861–71. doi:10.26719/emhj.19.036.
   Google Scholar
• Preventing pneumococcal disease among infants and young children. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2000;49(Rr–9):1–35.
   Google Scholar
• Prymula R, Schuerman L. 10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines. 2009;8(11):1479–500. doi:10.1586/erv.09.113.
   PubMed Web of Science ®Google Scholar
• Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. Drugs. 2010;70(15):1973–86. doi:10.2165/11205110-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Ktari S, Jmal I, Mroua M, Maalej S, Ben Ayed NE, Mnif B, Rhimi F, Hammami A. Serotype distribution and antibiotic susceptibility of Streptococcus pneumoniae strains in the south of Tunisia: a five-year study (2012–2016) of pediatric and adult populations. Int J Infect Dis. 2017;65:110–15. doi:10.1016/j.ijid.2017.10.015.
   PubMed Web of Science ®Google Scholar
• Knerer G, Ismaila A, Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ. 2012;15(1):61–76. doi:10.3111/13696998.2011.622323.
   PubMedGoogle Scholar
• Pugh SJ, Fletcher MA, Charos A, Imekraz L, Wasserman M, Farkouh R. Cost-Effectiveness of the pneumococcal conjugate vaccine (10- or 13-valent) versus no vaccination for a national immunization program in Tunisia or Algeria. Infect Dis Ther. 2019;8(1):63–74. doi:10.1007/s40121-018-0226-x.
   PubMed Web of Science ®Google Scholar
• United Nations. World population prospects 2019. Annual population (both sexes combined) of <1-year age group, for Tunisia, projections for 2020. [accessed 2021 Aug]. https://population.un.org/wpp/Download/Standard/Population/.
   Google Scholar
• World Health Organization. Life tables by country (Tunisia); global health observatory. General mortality by age for Tunisia. [acessed 2021 Aug]. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/gho-ghe-life-tables-by-country
   Google Scholar
• Rachdi M, Boutiba-Ben Boubaker I, Mahjoubi-Rhimi F, Smaoui H, Hammami A, Kéchrid A, Slim A, Ben Redjeb S. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated in Tunisia. J Med Microbiol. 2011;60(3):391–93. doi:10.1099/jmm.0.024901-0.
   PubMed Web of Science ®Google Scholar
• Marzouk M, Ferjani A, Bouafia N, Harb H, Ben Salem Y, Boukadida J. Serotype distribution and antimicrobial resistance of invasive and noninvasive pneumococcal isolates in Tunisia. Microb Drug Resist. 2015;21(1):85–89. doi:10.1089/mdr.2014.0084.
   PubMed Web of Science ®Google Scholar
• Charfi F, Smaoui H, Kechrid A. Non-Susceptibility trends and serotype coverage by conjugate pneumococcal vaccines in a Tunisian paediatric population: a 10-year study. Vaccine. 2012;30:G18–G24. doi:10.1016/j.vaccine.2012.07.017.
   PubMed Web of Science ®Google Scholar
• Raddaoui A, Simões AS, Baaboura R, Félix S, Achour W, Ben Othman T, Béjaoui M, Sá-Leão R, Ben Hassen A. Serotype distribution, antibiotic resistance and clonality of streptococcus pneumoniae isolated from immunocompromised patients in Tunisia. PLoS One. 2015;10(10):e0140390. doi:10.1371/journal.pone.0140390.
   PubMed Web of Science ®Google Scholar
• Midouni B, Mehiri E, Ghariani A, Draoui H, Essalah L, Bouzouita I, Raoult D, Slim-Saidi L, Fournier PE. Genetic diversity of streptococcus pneumoniae in Tunisia. Int J Antimicrob Agents. 2019;53(1):63–69. doi:10.1016/j.ijantimicag.2018.09.023.
   PubMed Web of Science ®Google Scholar
• Sfar MT, Amri F, Barsaoui A, Ben Becher S, Ben Dridi MF, Ben Helal K, Ben Jaballah N, Bouaziz A, Boughamoura L, Bousina S, et al. Epidemiology and expense of the streptococcus pneumoniæ meningitis in Tunisian chidren. Revue Maghrébine de Pédiatrie Hôpital D’Enfants. 2012;22(7):3–8.
   Google Scholar
• Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989;160(1):83–94. doi:10.1093/infdis/160.1.83.
   PubMed Web of Science ®Google Scholar
• Lu C-Y, Chung C-H, Huang L-M, Kruger E, Tan S-C, Zhang X-H, Chiu N-C. Cost-Effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan. Cost Eff Resour Alloc. 2020;18(1):30. doi:10.1186/s12962-020-00225-9.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Yothers G, Dagan R, Kilpi T, Pelton SI, Cohen R, Jacobs MR, Kaplan SL, Levy C, Lopez EL, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J. 2002;21(11):1008–16. doi:10.1097/00006454-200211000-00007.
   PubMed Web of Science ®Google Scholar
• Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J. 2004;23:1142–52.
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Camacho LAB, Coutinho ESF, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12): e0166736-e. doi:10.1371/journal.pone.0166736.
   Web of Science ®Google Scholar
• Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L, Buss-Younkin J, Farrar J, Pilishvili T, Whitney C, et al. Pneumococcal conjugate vaccine (PCV) product assessment I.V.A.C. [accessed 2020 Dec]. https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-productassessment-april-25-2017.pdf.
   Google Scholar
• World Health Organization. Regional technical advisory groups on immunization. [accessed 2020 Dec]. http://www.who.int/immunization/sage/regional/en/.
   Google Scholar
• Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–89. doi:10.1016/j.vaccine.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6): e1001657-e. doi:10.1371/journal.pmed.1001657.
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, Jokinen J, Eerola M, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, et al. Efficacy of a pneumococcal conjugate vaccine against acute Otitis media. N Engl J Med. 2001;344(6):403–09. doi:10.1056/NEJM200102083440602.
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels J-P, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367(9512):740–48. doi:10.1016/S0140-6736(06)68304-9.
   PubMed Web of Science ®Google Scholar
• Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J. Long-Term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36(15):1934–40. doi:10.1016/j.vaccine.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214–22. doi:10.1016/s0140-6736(12)61854-6.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization: pneumococcal vaccination coverage for Tunisia 2020. Global Health Observatory Data Repository. [accessed 2022 Jan]. https://immunizationdata.who.int/pages/coverage/PCV.html?CODE=TUN&ANTIGEN=PCV3&YEAR=.
   Google Scholar
• PAHO Revolving Fund. Vaccine Prices per dose 2020. [accessed 2021 Aug]. https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=vaccines-9979&alias=51457-revolving-fund-vaccine-prices-2020&Itemid=270&lang=fr.
   Google Scholar
• Constenla DO. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Rev Panam Salud Publica. 2008;24(2):101–12. doi:10.1590/s1020-49892008000800004.
   PubMed Web of Science ®Google Scholar
• Sachs JD Macroeconomics and health: investing in health for economic development. report of the commission on macroeconomics and health. [accessed 2021 Aug]. https://apps.who.int/iris/handle/10665/4243.
   Google Scholar
• World Health Organization: The World Health report 2002. Reducing risks, promoting healthy life. [accessed 2021 Aug]. http://www.who.int/whr/2002/en/whr02_en.pdf.
   Google Scholar
• World Bank National Accounts. GDP per capita in current US dollars, 2019. [accessed 2021 Aug]. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=TN.
   Google Scholar
• Consumer Price Index for Tunisia. United Nations office for the coordination of humanitarian affairs. [accessed 2021 Aug. https://data.humdata.org/dataset/faostat-prices-for-tunisia/resource/c5309d15-f25e-45c0-bb4c-a8ff5ecdb6d2.
   Google Scholar
• XE. Historical currency rates for Tunisia. [accessed 2021 Aug]. https://www.xe.com/currencytables/.
   Google Scholar
• Morrow A, De Wals P, Petit G, Guay M, Erickson LJ. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol. 2007;18(2):121–27. doi:10.1155/2007/713576.
   PubMed Web of Science ®Google Scholar
• Oh PI, Maerov P, Pritchard D, Knowles SR, Einarson TR, Shear NH. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther. 1996;18(1):160–82. doi:10.1016/s0149-2918(96)80188-3.
   PubMed Web of Science ®Google Scholar
• Bennett JE, Sumner W II, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr. 2000;154(1):43–48. doi:10.1001/pubs.PediatrAdolescMed.-ISSN-1072-4710-154-1-poa9043.
   Google Scholar
• Weinberger R, van der Linden M, Imöhl M, von Kries R. Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule. Vaccine. 2016;34(18):2062–65. doi:10.1016/j.vaccine.2016.02.043.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. doi:10.1016/s2213-2600(16)00052-7.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-Specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. doi:10.1016/s1473-3099(14)70822-9.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, Palmu AA., Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One. 2015;10(3):e0120290. doi:10.1371/journal.pone.0120290.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32(3):203–07. doi:10.1097/INF.0b013e318275614b.
   PubMed Web of Science ®Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232–38. doi:10.1016/j.vaccine.2013.10.032.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–73. doi:10.1093/cid/ciu524.
   PubMed Web of Science ®Google Scholar
• Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol. 2013;59(12):778–88. doi:10.1139/cjm-2013-0614.
   PubMed Web of Science ®Google Scholar
• Health Protection Agency. UK pneumococcal weekly surveillance 2014. [accessed 2018 June]. https://webarchivenationalarchives.gov.uk/20140714084352/https://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/.
   Google Scholar
• Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–502. doi:10.1016/S0140-6736(06)69637-2.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi:10.1086/648593.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vcrm vaccine. Pediatr Infect Dis J. 2009;28(4 Suppl):S66–76. doi:10.1097/INF.0b013e318199f8ef.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–71. doi:10.1016/s2213-2600(14)70060-8.
   PubMed Web of Science ®Google Scholar
• Knol MJ, Wagenvoort GHJ, Sanders EAM, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2015;21(11):2040–44. doi:10.3201/eid2111.140780.
   PubMed Web of Science ®Google Scholar
• Gomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O. Cost-Effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health. 2013;13(1):1025. doi:10.1186/1471-2458-13-1025.
   PubMedGoogle Scholar
• Zhang X-H, Nievera MC, Carlos J, Lucero M, Bibera G, Atienza MI, Topachevskyi O, Navarro-Locsin CG. Cost-effectiveness analysis of pneumococcal vaccination with the pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines. Value Health Reg Issues. 2014;3:156–66. doi:10.1016/j.vhri.2014.04.004.
   PubMedGoogle Scholar
• By A, Sobocki P, Forsgren A, Silfverdal S-A. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34(1):177–89. doi:10.1016/j.clinthera.2011.12.007.
   PubMed Web of Science ®Google Scholar
• Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AKH. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011;29(47):8564–74. doi:10.1016/j.vaccine.2011.09.025.
   PubMed Web of Science ®Google Scholar
• Clarke C, Bakaletz LO, Ruiz-Guiñazú J, Borys D, Mrkvan T. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines. 2017;16(7):1–14. doi:10.1080/14760584.2017.1333905.
   PubMed Web of Science ®Google Scholar